Liu Y, Liu HG, Zhao C. Intraperitoneal perfusion of endostatin improves the effectiveness and prolongs the prognosis of patients with gastric cancer. World J Gastrointest Oncol 2025; 17(4): 103131 [PMID: 40235905 DOI: 10.4251/wjgo.v17.i4.103131]
Corresponding Author of This Article
Cheng Zhao, Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No. 88 Changling Road, Xiqing District, Tianjin 300000, China. chengzi0845_cn@sina.com
Research Domain of This Article
Chemistry, Medicinal
Article-Type of This Article
Clinical Trials Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Apr 15, 2025 (publication date) through Mar 1, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Liu Y, Liu HG, Zhao C. Intraperitoneal perfusion of endostatin improves the effectiveness and prolongs the prognosis of patients with gastric cancer. World J Gastrointest Oncol 2025; 17(4): 103131 [PMID: 40235905 DOI: 10.4251/wjgo.v17.i4.103131]
World J Gastrointest Oncol. Apr 15, 2025; 17(4): 103131 Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.103131
Intraperitoneal perfusion of endostatin improves the effectiveness and prolongs the prognosis of patients with gastric cancer
Yong Liu, Hong-Gen Liu, Cheng Zhao
Yong Liu, Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300000, China
Yong Liu, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin 300000, China
Yong Liu, Tianjin Key Laboratory of Digestive Cancer, Tianjin Clinical Research Center for Cancer, Tianjin 300000, China
Hong-Gen Liu, Cheng Zhao, Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300000, China
Hong-Gen Liu, Cheng Zhao, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin Cancer Institute of Traditional Chinese Medicine, Tianjin 300380, China
Co-first authors: Yong Liu and Hong-Gen Liu.
Author contributions: Liu Y and Liu HG wrote the paper; Zhao C designed the paper. Liu Y and Liu HG contributed equally to this work as co-first authors.
Supported by Scientific Research Project of Tianjin Municipal Education Commission, No. 2018KJ015.
Institutional review board statement: The present study was approved by the Ethics Committee of the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine [No. TYLL202 (Zi) 004; March, 2021].
Clinical trial registration statement: This study is a sub topic of clinical research, and we obtained an ethical approval document. Our study included a small sample size, so we only registered the clinical trial in our hospital, not in the clinicaltrial.com. Based on the results of this study, we will conduct a multicenter study and carry out clinical registration in clinical trial.com.
Informed consent statement: All patients signed informed consent forms.
Conflict-of-interest statement: There are no conflicts of interest in this study.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Data sharing statement: We will share the data after accepted.
Corresponding author: Cheng Zhao, Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No. 88 Changling Road, Xiqing District, Tianjin 300000, China. chengzi0845_cn@sina.com
Received: November 10, 2024 Revised: January 2, 2025 Accepted: February 18, 2025 Published online: April 15, 2025 Processing time: 136 Days and 9.1 Hours
Abstract
BACKGROUND
Studies on the application of recombinant human endostatin (RH-endostatin) intraperitoneal perfusion in gastric cancer (GC) with malignant ascites are limited.
AIM
To explore the effectiveness, prognosis, and safety of intraperitoneal RH-endostatin perfusion in treating patients with GC and malignant ascites.
METHODS
Patients with GC and malignant ascites were divided into the cisplatin intraperitoneal perfusion (control group) group and the cisplatin combined with RH-endostatin intraperitoneal perfusion group (RH-endostatin group). Efficient ascites control, overall survival (OS), quality of life, and adverse events were observed, and possible influencing factors on prognosis outcomes analyzed.
RESULTS
We identified no significant differences in baseline characteristics between the control and RH-endostatin groups. The latter group had higher ascites control rates than the control group. Treatment methods were identified as an independent OS factor. Clinically, RH-endostatin-treated patients had significantly improved OS rates when compared with control patients, particularly in those with small and moderate ascites volumes. Quality of life improvements in control patients were significantly lower when compared with RH-endostatin patients. Adverse events were balanced between the groups.
CONCLUSION
Overall, intraperitoneal RH-endostatin improved treatment efficacy and prolonged prognosis in patients with GC and malignant ascites. This approach may benefit further clinical applications for treating GC.
Core Tip: Recombinant human endostatin (RH-endostatin) is an angiogenesis-inhibiting drug; the present study demonstrates that the intraperitoneal perfusion of RH-endostatin prolongs the prognosis of patients with gastric cancer (GC) and malignant ascites, particularly in patients with small and moderate ascites volumes. Intraperitoneal RH-endostatin perfusion significantly improves the quality of life in patients with GC and ascites, with less toxicity.
